Skip to main content
eureKING logo

eureKING — Investor Relations & Filings

Ticker · KINGS ISIN · FR0014009ON9 LEI · 96950078TLFWTM2QE234 PA Manufacturing
Open in API
Filings indexed 102 across all filing types
Latest filing 2023-08-11 AGM Information
Country FR France
Listing PA KINGS

About eureKING

https://eureking.com

eureKING is a Special Purpose Acquisition Company (SPAC) focused on the European healthcare sector, with a specific dedication to biomanufacturing. Founded in March 2022, the company's primary objective is to acquire and combine with European companies specializing in the production and manufacture of biopharmaceuticals. Through these strategic acquisitions, eureKING aims to build a leading European bio-CDMO (Contract Development and Manufacturing Organization). Its investment focus covers all stages of the biomanufacturing process, from clinical development through to commercialization and the full product lifecycle.

Recent filings

Filing Released Lang Actions
Résultats des votes des assemblées générale extraordinaire et spéciales du 11 août 2023
AGM Information Classification · 1% confidence The document is titled "Résultats des votes des assemblées générale extraordinaire et spéciales du 11 août 2023" (Results of the votes of the extraordinary and special general meetings of August 11, 2023). It details the voting outcomes across several special meetings concerning different classes of shares and warrants (Market Shares, Market Warrants, Founders' Shares A1, A2, etc.). The core content is the official tabulation of votes ('Pour', 'Contre', 'Abstention') on resolutions, which directly relates to the outcome of a shareholder vote. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM/EGM context, the specific focus on the *results* of the votes makes DVA the most precise classification over AGM-R.
2023-08-11 French
eureKING announces the signing of an agreement to purchase full ownership interest in SCTbio, taking a step closer in building a new European bio-CDMO leader
Regulatory Filings Classification · 1% confidence The document is a press release announcing a significant corporate action: the signing of an agreement by eureKING to acquire full ownership interest in SCTbio. It details the strategic rationale, valuation (€17.5 million enterprise value), financing plans (cash and share issuance), and the intended sequence relative to a prior acquisition (Skyepharma). This type of announcement, detailing a major transaction like an acquisition, is typically classified as a Capital/Financing Update (CAP) or sometimes a Regulatory Filing (RNS) if it's a mandatory disclosure. Since the core subject is the financing and capital structure change resulting from the acquisition, 'CAP' is the most specific fit among the provided options, as it directly relates to fundraising and capital structure changes necessary to fund the deal. It is not a formal 10-K, ER, or IR, but a specific announcement about a transaction.
2023-08-09 English
eureKING annonce la signature d'un accord sur l'achat de la totalité des parts de SCTbio, franchissant ainsi une étape dans la création d'un nouveau leader européen de la bio-CDMO
M&A Activity Classification · 1% confidence The document is a press release dated August 9, 2023, announcing that eureKING has signed an agreement to acquire 100% of SCTbio. It details the terms of the transaction, the strategic rationale (creating a European bio-CDMO leader), financial considerations (enterprise value, cash purchase price), and the intended financing structure (involving existing shareholder commitments and a potential PIPE). This type of announcement, detailing a significant corporate transaction (acquisition/merger) and its financial implications, falls under the category of M&A Activity (TAR). It is not a full annual report (10-K), an interim report (IR), or a simple earnings release (ER). Since it is a detailed announcement of a transaction, it is classified as TAR rather than the general fallback (RNS).
2023-08-09 French
eureKING and Skyepharma revise the terms of their business combination
M&A Activity Classification · 1% confidence The document is a press release dated August 8, 2023, announcing a revision to the terms of a business combination agreement between two entities, eureKING (a SPAC) and Skyepharma (which is acquiring Oleron Pharma). It details changes in the equity/cash split, governance, financing plans (PIPE), and crucially, calls for extraordinary meetings of security holders on August 11, 2023, to approve necessary amendments to the articles of association to allow the transaction to proceed or trigger liquidation. This document is a substantive announcement detailing a major corporate transaction (M&A/Financing) and related shareholder votes, not just a brief notice of a report. Since it details a merger/acquisition proposal, the most fitting category is M&A Activity (TAR). It is too detailed to be a simple Regulatory Filing (RNS) or a Report Publication Announcement (RPA).
2023-08-08 English
eureKING et Skyepharma ajustent les conditions de leur regroupement d'entreprises
M&A Activity Classification · 1% confidence The document is a press release dated August 8, 2023, detailing adjustments to the terms of a business combination (regroupement d'entreprises) between eureKING (a SPAC) and Skyepharma. It discusses changes in the cash vs. share split, governance, financing plans (PIPE), and crucially, announces extraordinary general meetings (assemblées générales extraordinaires) scheduled for August 11, 2023, to vote on necessary amendments to the company's articles of association (Statuts d'eureKING) and to potentially open a redemption period for SPAC shareholders. The text explicitly mentions the need for shareholder votes on the transaction and related structural changes. This content strongly aligns with the purpose of soliciting shareholder votes and providing necessary information for that vote, which falls under Proxy Solicitation & Information Statement (PSI). While it relates to a merger (TAR), the immediate focus and action required from shareholders (voting on structural changes and redemption rights) points more directly to PSI. It is not the final merger agreement itself, nor is it a general regulatory filing (RNS) given its specific focus on the shareholder vote mechanics.
2023-08-08 French
Mise à disposition des documents préparatoires aux assemblées du 11 août 2023
AGM Information Classification · 1% confidence The document is titled "Mise à disposition des documents préparatoires aux assemblées du 11 août 2023" (Making available of preparatory documents for the meetings of August 11, 2023). It explicitly states that preparatory documents for the General and Special Meetings are being made available and provides a link where they can be consulted. This structure—announcing the availability of materials for an upcoming shareholder meeting—strongly indicates a communication related to soliciting votes or providing information ahead of that meeting. The most fitting category is Proxy Solicitation & Information Statement (PSI), as it relates to materials provided before a shareholder meeting where votes are required on specific resolutions (like the proposed acquisition and warrant changes). While it mentions the meeting date, it is not the final voting results (DVA) nor the full AGM presentation (AGM-R). It is an announcement about the availability of proxy materials.
2023-07-24 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.